Safety and immunogenicity of high molecular weight polysaccharide vaccine from immunotype 1 Pseudomonas aeruginosa.
Open Access
- 1 February 1982
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 69 (2) , 303-308
- https://doi.org/10.1172/jci110453
Abstract
The safety and immunogenicity of a high molecular weight polysaccharide from immunotype 1 Pseudomonas aeruginosa were tested in a dose response fashion in adult volunteers. The vaccine lacked toxicity and pyrogenicity for experimental animals. Doses of 50, 75, 150, or 250 microgram were given to groups of individuals as a single dose subcutaneous injection. Doses of 150 and 250 microgram were associated with a significant rise in binding and opsonic antibody at 2 wk postimmunization. Titers remained unchanged for up to 6 mo. The vaccine was almost devoid of toxicity, eliciting no more than a slightly sore and tender arm at the site of injection. High molecular weight polysaccharide antigen appears to induce a good immune response following vaccination that is effective in mediating opsonophagocytic killing of live P. aeruginosa organisms.This publication has 20 references indexed in Scilit:
- Correlation of the biologic responses of C3H/HEJ mice to endotoxin with the chemical and structural properties of the lipopolysaccharides from Pseudomonas aeruginosa and Escherichia coli.The Journal of Immunology, 1981
- CONTROLLED TRIAL OF PSEUDOMONAS IMMUNOGLOBULIN AND VACCINE IN BURN PATIENTSThe Lancet, 1980
- Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man.Journal of Clinical Investigation, 1979
- A New Polyvalent Pseudomonas VaccineJournal of Medical Microbiology, 1977
- Pseudomonas bacteremiaThe American Journal of Medicine, 1976
- Immunization against Pseudomonas in Infection after Thermal InjuryThe Journal of Infectious Diseases, 1974
- Advances in the management of Pseudomonas aeruginosa infections in cancer patientsPublished by Elsevier ,1973
- Human Immunity to Pseudomonas aeruginosa. I. In-Vitro Interaction of Bacteria, Polymorphonuclear Leukocytes, and Serum FactorsThe Journal of Infectious Diseases, 1972
- Human Immunity to Pseudomonas aeruginosa. II. Relationship between Heat-Stable Opsonins and Type-Specific LipopolysaccharidesThe Journal of Infectious Diseases, 1972
- Type-specific immunity in pseudomonas diseases.1972